Needham & Company downgraded Intercept Pharmaceuticals (NASDAQ: ICPT) from Buy to Hold, citing no substantial catalysts in 2017.Analyst Alan Carr ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE